Alvotech Issues New Shares to Holders of Convertible Bonds
July 01, 2024 17:35 ET
|
Alvotech
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech gefur út nýja hluti í skiptum fyrir breytileg skuldabréf
July 01, 2024 17:35 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hefði gefið út nýja hluti í skiptum fyrir breytileg skuldabréf, sem upprunalega voru gefin út af Alvotech í nóvember og desember 2022 og voru með...
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
July 01, 2024 05:10 ET
|
Alvotech
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech kynnir áætlaðar mettekjur og EBITDA framlegð á öðrum ársfjórðungi 2024
July 01, 2024 05:10 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) kynnti í dag eftirfarandi óendurskoðaða áætlun um rekstrarniðurstöðu annars ársfjórðungs og á fyrri helmingi ársins 2024. Reiknað er með mettekjum Alvotech frá upphafi á...
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
July 01, 2024 05:10 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key...
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
June 26, 2024 04:50 ET
|
Alvotech
REYKJAVIK, Iceland , June 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Eigendur meirihluta breytilegra skuldabréfa Alvotech nýta rétt til að breyta yfir í hlutabréf
June 26, 2024 04:50 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að eigendur meirihluta breytilegra skuldabréfa félagins sem upphaflega voru útgefin 16. nóvember og 20. desember 2022 með lokagjalddaga 20. desember 2025, hafi...
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
June 26, 2024 04:50 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that holders of the majority of...
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
June 18, 2024 04:01 ET
|
Alvotech
Advanz Pharma secures rights to commercialize Alvotech’s biosimilar candidate for Eylea® in Europe Advanz Pharma will leverage its existing specialty and hospital capabilities in Europe to ensure...
Alvotech og Advanz Pharma undirrita samning um markaðssetningu í Evrópu á fyrirhugaðri líftæknilyfjahliðstæðu við Eylea
June 18, 2024 04:00 ET
|
Alvotech
Advanz Pharma fær rétt til markaðssetningar fyrirhugaðrar líftæknilyfjahliðstæðu við Eylea í Evrópu, en Alvotech þróar nú tvær útgáfur lyfsinsAdvanz Pharma mun nýta þekkingu á markaðssetningu...